Three years after AbbVie stood at the edge of a major patent cliff with the loss of exclusivity for immunology ...
AbbVie Inc. raised its full-year profit forecast after quarterly results beat estimates, a sign of confidence amid growing ...
AbbVie is scheduled to report Q1 earnings on April 29, before market open, with analysts expecting growth recovery both in ...
Oruka Therapeutics’ long-acting plaque psoriasis candidate cleared the skin of 63.5% of patients in a phase 2a trial, leading ...
On April 30, Bank of America analyst Tim Anderson upgraded AbbVie Inc. (NYSE:ABBV) to Buy from Neutral. It also lifted the ...
By Kamal Choudhury and Christy Santhosh April 29 (Reuters) - AbbVie on Wednesday reported better-than-expected quarterly ...
AbbVie (NYSE: ABBV) today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval for SKYRIZI® (risankizumab-rzaa) for subcutaneous (SC) ...
Skyrizi was the top Rx and over-the-counter (OTC) pharma brand during July, according to data released by iSpot.tv on Monday afternoon. Skyrizi recorded an impressions share of voice (SOV) of 5.18%, ...
Skyrizi is a brand-name prescription drug used in the treatment of certain autoimmune conditions, including psoriasis and psoriatic arthritis. Skyrizi is an interleukin-23 (IL-23) inhibitor, which is ...
Skyrizi (risankizumab-rzaa) is a biologic medication doctors prescribe to treat certain autoimmune and inflammatory conditions. Like any medication, it can cause side effects. But is one of Skyrizi’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results